

MARKSANS PHARMA LIMITED

Regd. Office: 11th Floor, Lotus Business Park Off. New Link Road, Andheri West, Mumbai-400053

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2010

Rs. In Lacs

Sr. No.	PARTICULARS	For the quarter ended on			For the period ended on			For the year ended on 31st March 10 (AUDITED)
		31.12.2010 (UNAUDITED)	31.12.2009 (UNAUDITED)	31.12.2010 (UNAUDITED)	31.12.2009 (UNAUDITED)	31.12.2009 (UNAUDITED)		
1	Income							
a>	Net Sales/ Income from Operations	3,492.83	6,294.10	12,143.30	14,854.92	19,956.21		
b>	Other Operating Income	31.89	67.31	68.57	136.38	160.37		
	Total Income	3,524.72	6,361.41	12,211.87	14,991.30	20,116.58		
2	Expenditure							
a>	(Increase)/Decrease in stock in trade	2.74	1,508.68	(1.93)	1,646.81	1,198.19		
b>	Consumption of Material & Purchases	2,815.14	3,021.10	8,571.78	9,316.73	13,443.92		
c>	Employee Cost	290.57	306.69	815.19	815.65	1,069.13		
d>	Depreciation	88.06	247.91	482.70	738.62	983.92		
e>	Other Expenditure	353.90	559.04	1,147.49	1,542.24	1,880.92		
	Total Expenditure	3,550.41	5,643.42	11,015.23	14,060.05	18,576.08		
3	Profit from Operations before other Income							
	Interest & Exceptional Items (1-2)	(25.69)	717.99	1,196.64	931.25	1,540.50		
4	Other Income							
5	Profit before Interest & Exceptional item (3+4)	(25.69)	717.99	1,196.64	931.25	1,540.50		
6	Interest	357.22	505.22	1,252.58	1,416.61	1,477.83		
7	Profit after Interest but before Tax Exceptional items	(382.91)	212.77	(55.94)	(485.36)	62.67		
8	Exceptional Items							
9	Profit/(Loss) from Ordinary activities before Tax (7+8)	(382.91)	212.77	(55.94)	(485.36)	62.67		
10	Tax Expenses- Earlier year income tax		100.00		100.00	33.69		
11	Net Profit/(loss) from Ordinary activities after tax(9-10)	(382.91)	112.77	(55.94)	(585.36)	28.98		
	Less: Extraordinary Item-(Loss)/Profit on sale of 12 AP1 divisor/fixed assets	175.83		(7,936.39)				
13	Net Profit (Loss) for the period (11-12)	(207.08)	112.77	(7,992.33)	(585.36)	28.98		
14	Paid up Equity Share Capital (Face Value Re. 1 each)	3,678.07	3,678.05	3,678.07	3,678.05	3,678.05		
15	Reserve Excluding Revaluation Reserve as per Balance sheet of Previous Accounting Year							
16	a> Earnings Per Share (Basic & Diluted) (before extraordinary items Rs.)	(0.10)	0.03	(0.02)	(0.16)	12.536.52		0.01
	b> Earnings Per Share(Basic & Diluted) (after Extraordinary Items- Rs.)	(0.06)	0.03	(2.17)	(0.16)	0.01		
17	Aggregate of Public Shareholding:							
	- Number of Shares	189,823,694	189,822,361	189,823,694	189,822,361	189,822,361		189,822,361
	- Percentage of Holding	51.61%	51.61%	51.61%	51.61%	51.61%		51.61%
18	Promoters and Promoter group Shareholdings	177,983,510	177,983,510	177,983,510	177,983,510	177,983,510		177,983,510
	a> Pledged/Encumbered	NIL	NIL	NIL	NIL	NIL		NIL
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N/A	N/A	N/A	N/A	N/A		N/A
	- Percentage of Holding (as a % of the total share capital of the Company)	N/A	N/A	N/A	N/A	N/A		N/A
	a> - Non-encumbered	177,983,510	177,983,510	177,983,510	177,983,510	177,983,510		177,983,510
	- Number of Shares	177,983,510	177,983,510	177,983,510	177,983,510	177,983,510		177,983,510
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	100%	100%	100%	100%	100%		100%
	- Percentage of Holding (as a % of the total share capital of the Company)	48.39%	48.39%	48.39%	48.39%	48.39%		48.39%

Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14.02.2011.
- 2 The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- 3 The company has on 28th July ,2010 entered into a Business Transfer Agreement with Kores(India) Limited for sale and transfer of its Active Pharmaceutical Ingredients (API) business together with its Manufacturing facilities located at plot Nos.A-88 and D-10,MIDC, Kurkumbh, Pune , Maharashtra.
- 4 The Company has issued USD 50 Million zero coupon Foreign Currency Convertible Bonds in November-2005. No Provision have been made during the year for foreign exchange difference account and for Yield to Maturity(YTM) in case of Foreign Currency Convertible Bond. The bonds have become due for redemption on 09th November,2010 and were not redeemed. The Company is in constructive conversations with bond holders for the restructuring of the bonds.
- 5 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 6 There were no pending investor complaints at the beginning and end of the Quarter. The Company has not received any investor complaint during the Quarter.
- 7 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

For MARKSANS PHARMA LIMITED

MARK SALDANHA
Managing Director.



Place: Mumbai.
Date: 14.02.2011
Visit us at www.marksanspharma.com

MARKSANS PHARMA LIMITED

Regd. Office: 11th Floor, Lotus Business Park, Off. New Link Road, Andheri West, Mumbai-400053

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st December 2010

Sr. No.	PARTICULARS	For the Quarter ended on			For the Period ended on			Rs. in Lacs
		31.12.2010 (UNAUDITED)	31.12.2009 (UNAUDITED)	31.12.2010 (UNAUDITED)	31.12.2009 (UNAUDITED)	31st March 10 (AUDITED)		
1	Income							
a>	Net Sales/ Income from Operations	7,534.48	9,317.40	22,818.83	26,678.29	35,936.58		
b>	Other Operating Income	33.59	70.74	73.28	157.46	183.93		
	Total Income	7,568.07	9,388.14	22,892.11	26,835.75	36,120.51		
2	Expenditure							
a>	(Increase)/Decrease in stock in trade	(105.01)	1,671.94	98.37	1,491.97	1,583.02		
b>	Consumption of Material & Purchases	5,366.19	4,668.53	15,290.79	17,550.43	24,086.08		
c>	Employee Cost	979.19	809.95	2,609.55	2,636.68	3,578.19		
d>	Depreciation	119.31	244.18	575.21	1,011.56	1,547.45		
e>	Other Expenditure	924.52	1,059.74	2,717.68	3,262.24	4,325.31		
	Total Expenditure	7,284.20	8,454.34	21,291.60	25,952.88	35,120.05		
3	Profit from Operations before other income							
	Interest & Exceptional Items (1-2)	283.87	933.80	1,600.51	882.87	1,000.46		
4	Other Income	-	-	-	-	-		
5	Profit before Interest & Exceptional item (3+4)	283.87	933.80	1,600.51	882.87	1,000.46		
6	Interest	420.92	581.26	1,554.63	1,728.79	1,923.12		
7	Profit after Interest but before Tax Exceptional Items	(137.05)	352.54	45.88	(845.92)	(922.66)		
8	Exceptional items	-	-	-	-	-		
9	Profit/(Loss) from Ordinary activities before Tax (7+8)	(137.05)	352.54	45.88	(845.92)	(922.66)		
10	Tax Expenses - Earlier year Income tax	-	98.71	-	132.25	39.51		
11	Net Profit/(loss) from Ordinary activities after tax(9-10)	(137.05)	253.83	45.88	(978.17)	(962.17)		
12	a> Less:- Minority Interest	31.98	(4.54)	63.14	25.20	42.18		
	b> Less: Extraordinary Item-(Loss)/Profit on sale of API division/Fixed assets	175.83	-	(7,936.39)	-	-		
13	Net Profit/ (Loss) for the period (11-12)	6.80	258.37	(7,953.65)	(1,003.37)	(1,004.35)		
14	Paid up Equity Share Capital (Face Value Re.1 each)	3,678.07	3,678.05	3,678.07	3,678.05	3,678.05		
15	Reserve Excluding Revaluation Reserve as per Balance sheet of Previous Accounting year	-	-	-	-	-		
16	a> Earnings Per Share (Basic & Diluted) (before extraordinary items, Rs.)	(0.04)	0.07	0.01	(0.27)	11,081.44		
	b> Earnings Per Share (Basic & Diluted) (after Extraordinary items- Rs.)	0.002	0.07	(2.16)	(0.27)	(0.27)		
17	Aggregate of Public Shareholding:							
	- Number of Shares	189,823,694.00	189,822,361.00	189,823,694.00	189,822,361.00	189,822,361.00		
	- Percentage of Holding	51.61%	51.61%	51.61%	51.61%	51.61%		
18	Promoters and Promoter group Shareholdings							
a>	- Pledged/Encumbered	177,983,510.00	177,983,510.00	177,983,510.00	177,983,510.00	177,983,510.00		
	- Number of Shares	NIL	NIL	NIL	NIL	NIL		
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N/A	N/A	N/A	N/A	N/A		
	- Percentage of Holding (as a % of the total share capital of the Company)	N/A	N/A	N/A	N/A	N/A		
a>	- Non-encumbered	177,983,510.00	177,983,510.00	177,983,510.00	177,983,510.00	177,983,510.00		
	- Number of Shares	100%	100%	100%	100%	100%		
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	48.39%	48.39%	48.39%	48.39%	48.39%		
	- Percentage of Holding (as a % of the total share capital of the Company)	48.39%	48.39%	48.39%	48.39%	48.39%		




Sr. No.	PARTICULARS	For the Quarter ended on		For the Period ended on		For the year ended on 31st March 10 (AUDITED)
		31.12.2010 (UNAUDITED)	31.12.2009 (UNAUDITED)	31.12.2010 (UNAUDITED)	31.12.2009 (UNAUDITED)	
	Revenue	3,524.72	6,361.41	12,211.87	14,991.30	20,116.58
	Profit Before Tax from Ordinary activities	(382.91)	212.77	(55.94)	(485.36)	62.67
	Profit After Tax from Ordinary activities	(382.91)	112.77	(55.94)	(585.36)	28.98

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14.02.2011.
- The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- The company has on 28th July, 2010 entered into a Business Transfer Agreement with Kores(India) Limited for sale and transfer of its Active Pharmaceutical Ingredients (API) business together with its Manufacturing facilities located at plot Nos.A-88 and D-10,MIDC, Kurkumbh, Pune , Maharashtra.
- The Company has issued USD 50 Million zero coupon Foreign Currency Convertible Bonds in November-2005. No Provision have been made during the year for foreign exchange difference account and for Yield to Maturity(YTM) in case of Foreign Currency Convertible Bond. The bonds have become due for redemption on 09th November, 2010 and were not redeemed. The Company is in constructive conversations with bond holders for the restructuring of the bonds.
- The current outstanding of bonds is USD 43,999,000. The accretiated value of bonds with YTM is 145.20% of the principle value.
- The Consolidated Financial Statements Include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (U.K.) Limited.
- The Consolidated Financial Statements are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by the Institute of Chartered Accountants of India.
- The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- There were no pending investor complaints at the beginning and end of the Quarter. The Company has not received any investor complaint during the Quarter.
- Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

Place: Mumbai.
Date: 14.02.2011
Visit us at www.marksanspharma.com

For MARKSANS PHARMA LIMITED

MARK SALDANHA
 Managing Director.

